Skip to main content
Oncotarget logoLink to Oncotarget
. 2022 Apr 1;13:583–584. doi: 10.18632/oncotarget.28109

Correction: Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin

Sixian Liang 1,*, Xun Peng 2,*, Xiaoli Li 1, Ping Yang 1, Linhao Xie 1, Yaochen Li 3, Caiwen Du 1,, Guojun Zhang 3,
PMCID: PMC8979100  PMID: 35391718

This article has been corrected: In Figure 4C, panel ‘o’ contains a partial accidental overlap of panel ‘e’. The corrected Figure 4, produced using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Figure 4.

Figure 4

(C) Immunohistochemical staining of xenograft tumors for p53, Bax, Bcl-2 and caspase-3 (magnification = 40×).

Original article: Oncotarget. 2015; 6:1020–1030. 1020-1030. https://doi.org/10.18632/oncotarget.2741


Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES